Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic ...

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) ...

Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...

Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...